Abstract
Background: Until now, Metformin remains the first-line pharmacologic treatment for type 2 diabetes (T2D). This drug is the gold standard in the management of patients with T2D. (BCC) abnormalities in diabetics treated with metformin are not widely described in the literature.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
